Score Overview
Explore the 2021 public Archive ranking →
Abbott Laboratories fundamental performance
Between 2015 and 2025, revenue grew from $ 20.40B to $ 44.32B and net income grew from $ 4.42B to $ 6.52B. Revenue increased in 9 of those 10 years; net income in 5.
Across Abbott Laboratories's full reported history, from 1985 to 2025, revenue grew from $ 3.36B to $ 44.32B and net income grew from $ 465M to $ 6.52B. Revenue increased in 90% of the years measured; net income in 71%.
Abbott Laboratories currently holds a 20-year HDB Score of 4.9 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-01 | $ 108.93 | — |
1 Year2025-08-29 | $ 129.66 | -15.99% |
5 Years2021-09-01 | $ 115.59 | -5.76% |
10 Years2016-09-01 | $ 35.04 | 210.88% |
20 Years2006-09-01 | $ 14.69 | 7x |
30 Years1996-08-30 | $ 4.85 | 22x |
| Period | Last Price2026-09-01 | 1 Year2025-08-29 | 5 Years2021-09-01 | 10 Years2016-09-01 | 20 Years2006-09-01 | 30 Years1996-08-30 |
|---|---|---|---|---|---|---|
| Price | $ 108.93 | $ 129.66 | $ 115.59 | $ 35.04 | $ 14.69 | $ 4.85 |
| Return | — | -15.99% | -5.76% | 210.88% | 7x | 22x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 45.13B | $ 6.27B | |
| 2025 | $ 44.32B | $ 6.52B | $ 8.93B |
| 2024 | $ 41.95B | $ 13.40B | $ 7.96B |
| 2023 | $ 40.10B | $ 5.72B | $ 7.27B |
| 2022 | $ 43.65B | $ 6.93B | $ 10.17B |
| 2021 | $ 43.07B | $ 7.07B | $ 10.24B |
| 2020 | $ 34.60B | $ 4.49B | $ 7.14B |
| 2019 | $ 31.90B | $ 3.68B | $ 4.14B |
| 2018 | $ 30.57B | $ 2.36B | $ 4.08B |
| 2017 | $ 27.39B | $ 477M | $ 9.61B |
| 2016 | $ 20.85B | $ 1.40B | $ 18.77B |
| 2015 | $ 20.40B | $ 4.42B | $ 6.12B |
| 2014 | $ 20.24B | $ 2.28B | $ 4.46B |
| 2013 | $ 21.84B | $ 2.57B | $ 8.09B |
| 2012 | $ 39.87B | $ 5.96B | $ 15.17B |
| 2011 | $ 38.85B | $ 4.72B | $ 8.09B |
| 2010 | $ 35.16B | $ 4.62B | $ 7.32B |
| 2009 | $ 30.76B | $ 5.74B | $ 9.93B |
| 2008 | $ 29.52B | $ 4.88B | $ 5.07B |
| 2007 | $ 25.91B | $ 3.60B | $ 2.82B |
| 2006 | $ 22.47B | $ 1.71B | $ 1.37B |
| 2005 | $ 22.33B | $ 3.37B | $ 2.95B |
| 2004 | $ 19.68B | $ 3.23B | $ 2.05B |
| 2003 | $ 19.68B | $ 2.75B | $ 1.28B |
| 2002 | $ 17.68B | $ 2.79B | $ 966M |
| 2001 | $ 16.28B | $ 1.55B | $ 713M |
| 2000 | $ 13.74B | $ 2.78B | $ 1.15B |
| 1999 | $ 13.17B | $ 2.44B | $ 723M |
| 1998 | $ 12.47B | $ 2.33B | $ 383M |
| 1997 | $ 11.88B | $ 2.07B | $ 259M |
| 1996 | $ 11.01B | $ 1.88B | $ 123M |
| 1995 | $ 10.01B | $ 1.68B | $ 315M |
| 1994 | $ 9.15B | $ 1.51B | $ 315M |
| 1993 | $ 8.40B | $ 1.39B | $ 378M |
| 1992 | $ 7.85B | $ 1.23B | $ 116M |
| 1991 | $ 6.87B | $ 1.08B | $ 60M |
| 1990 | $ 6.15B | $ 965M | $ 34M |
| 1989 | $ 5.37B | $ 859M | $ 13M |
| 1988 | $ 4.93B | $ 752M | $ 582M |
| 1987 | $ 4.38B | $ 632M | $ 519M |
| 1986 | $ 3.80B | $ 540M | $ 481M |
| 1985 | $ 3.36B | $ 465M | $ 437M |
Where Abbott Laboratories has ranked, year by year
Each point is that year's ranking on ten years of fundamentals, as a share of every company we could rank at the time. Higher is better. We show the share rather than the place because the number of companies grows — 193 in 1996, 2,060 in 2021 — so the same place means something different at either end.
Reached the top 50 on HDB Score in 6 years, the longest run being 6 in a row — but not in 2021.
1996: 3.1% · 2021: 61.3% · free through 2021 · longest runs
See where ABT ranks today
You're looking at Abbott Laboratories's public company record. Membership adds the current comparative layer and continues its ranking history through recent years.
- Current market-wide rankings across 3,839 covered companies
- See where Abbott Laboratories ranks today
- Complete current Score Views across every period
- Current Tenure and recent Archive years
- Portfolio and member features
$99/year $149 founding price
Become a Member30-day money-back guarantee.
